Krzysztof W. Selmaj
Olsztyn, WN, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.
Journal: Neurology and therapy
Published: June 01, 2026
Unique expression pattern of circulating exosomal miRNA correlates with CNS pathology.
Journal: Frontiers in immunology
Published: April 05, 2026
Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study.
Journal: Neurology and therapy
Published: March 26, 2026
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.
Journal: JAMA neurology
Published: February 16, 2026
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.
Journal: Frontiers in immunology
Published: December 19, 2025
Failed, Inconclusive or Interrupted Trials in Multiple Sclerosis: 2020-2024 Update.
Journal: Multiple sclerosis and related disorders
Published: December 10, 2025
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study.
Journal: Neurology and therapy
Published: December 03, 2025
Neuro-behcet's syndrome: epidemiology, mechanisms, and emerging strategies in diagnosis and treatment.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: December 02, 2025
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 05, 2025
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
Journal: Lancet (London, England)
Published: October 30, 2025
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
Journal: Lancet (London, England)
Published: October 30, 2025
Last Updated: 09/26/2026